Methergin (Methylergometrine Maleate)

Methylergometrine maleate acts as a partial agonist at serotonin 5‑HT2 and alpha‑adrenergic receptors while blocking dopamine receptors. This pharmacologic profile raises intracellular calcium in uterine smooth‑muscle cells, leading to strong, sustained uterine contractions that help control bleeding.

The specific dose of Methergin is determined by the prescribing clinician based on the patient’s condition, weight, and clinical response. Healthcare professionals follow local guidelines and adjust the regimen as needed for safety and efficacy.

Methergin is contraindicated in pregnancy (Category X) because it can cause fetal harm. It is also not recommended for breastfeeding mothers, as the drug may be excreted in breast milk and affect the infant.

To order Methergin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Methergin belongs to the ergot alkaloid class, offering a longer duration of uterine contraction compared with oxytocin, which has a rapid onset but shorter effect. Unlike prostaglandin analogues, Methergin’s mechanism involves serotonin and adrenergic pathways, providing an alternative when other uterotonics are ineffective or contraindicated.

Methergin should be stored at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Methergin is administered orally. The exact route (tablet, capsule, or liquid) and dosing schedule are prescribed by a qualified healthcare professional, who will consider the patient’s clinical situation and monitor response.

Serious risks include severe hypertension, coronary artery spasm, myocardial infarction, stroke, severe allergic reactions, and rare uterine rupture. Patients should be monitored closely for cardiovascular symptoms and any signs of allergic response during and after administration.

Methergin should not be used by individuals with known hypersensitivity to ergot alkaloids, those with uncontrolled hypertension, coronary artery disease, or a history of cerebrovascular disorders. It is also contraindicated in pregnant women and should be avoided during breastfeeding.